Abstract
Introduction
As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine.
Materials and methods
German females (n = 437; 9–23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16–23, abnormal cervical cytology and sexually transmitted diseases.
Results
Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects <17 years were naïve to the four vaccine types.
Discussion
The results of the vaccine trials have demonstrated that it is worth administering prophylactic HPV vaccines before sexual debut; however, none of these sexually active German women were positive to all four types and most were positive to only one type. Thus, all women had the potential to benefit from vaccination with a quadrivalent HPV vaccine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bosch FX, Manos MM, Muñoz N et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87:796–802. doi:10.1093/jnci/87.11.796
Gissmann L, zur Hausen H (1980) Partial characterization of viral DNA from human genital warts (condylomata acuminata). Int J Cancer 25:605–609. doi:10.1002/ijc.2910250509
Derkay CS, Darrow DH (2000) Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 33:1127–1142. doi:10.1016/S0030-6665(05)70270-X
Hildesheim A, Herrero R, Wacholder S et al (2007) Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743–753. doi:10.1001/jama.298.7.743
Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943. doi:10.1056/NEJMoa061760
FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927. doi:10.1056/NEJMoa061741
Delere Y, Meyer C, Reiter S (2007) Universal immunisation with human papillomavirus (HPV) vaccine among females aged 12–17 recommended in Germany. Euro Surveill 12:E0704052
Committee on Adolescent Health Care, ACOG Working Group on Immunization (2006) ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 108:699–705
Garland SM, Steben M, Hernandez-Avila M et al (2007) Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14:792–795. doi:10.1128/CVI.00478-06
Block SL, Nolan T, Sattler C et al (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135–2145. doi:10.1542/peds.2006-0461
Bryan J, Taddeo F, Skulsky D et al (2006) Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas. J Med Virol 78:117–124. doi:10.1002/jmv.20512
Solomon D, Davey D, Kurman R et al (2002) The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287:2114–2119. doi:10.1001/jama.287.16.2114
Dias D, Van Doren J, Schlottmann S et al (2005) Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diag Lab Immunol 12:959–969. doi:10.1128/CDLI.12.8.959-969.2005
Paavonen J (2008) Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin 24:1623–1634. doi:10.1185/03007990802068151
de Villiers EM, Wagner D, Schnieder A et al (1992) Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecol Oncol 44:33–39. doi:10.1016/0090-8258(92)90008-7
Schneider A, Hoyer H, Lotz B et al (2000) Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89:529–534. doi:10.1002/1097-0215(20001120)89:6<529::AID-IJC11>3.0.CO;2-G
Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170. doi:10.1016/S0140-6736(07)60946-5
Clad A, Prillwitz J, Hintz KC et al (2001) Discordant prevalence of Chlamydia trachomatis in asymptomatic couples screened using urine ligase chain reaction. Eur J Clin Microbiol Infect Dis 20:324–328
Koch J, Kirschner W, Schaefer A (1997) Bestimmung der Praevalenz genitaler HPV- und Chlamydia trachomatis-Infektionen in einem repraesentativen Querschnitt der weiblichen Normalbevoelkerung in Berlin. Infektionsepidemiol Forsch 2:1–7
Griesinger G, Gille G, Klapp C et al (2007) Sexual behaviour and Chlamydia trachomatis infections in German female urban adolescents, 2004. Clin Microbiol Infect 13:436–439. doi:10.1111/j.1469-0691.2006.01680.x
Robert-Koch-Institut EU bordernet surveillance on HIV/STD. http://www.rki de/cln_049/nn_196664/DE/Content/InfAZ/S/STD/Studien/Bordernet/Bordernet_inhalt html#doc207858bodyText3, 2007
Madeleine MM, Anttila T, Schwartz SM et al (2007) Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 120:650–655. doi:10.1002/ijc.22325
Franceschi S, Smith JS, van den BA et al (2007) Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study. Sex Transm Dis 34:563–569
Acknowledgments
Merck Research Laboratories, a division of Merck and Co., Inc., funded this study in its entirety. A portion of these data were presented at the 2007 Joint Annual Bavarian-Austrian Congress on Gynaecology and Obstetrics. Drs Barthell, Woelber, Hellner, Camerer, Gieseking, Hauschild, and Friese report having received funding from Merck through their respective institutions to conduct clinical trials of this vaccine. Drs Sings and Barr are employees of Merck and Co., Inc. and hold stock and/or stock options. Dr Barthell has received lecture fees from speaking at the invitation of Sanofi-Pasteur Merck Sharp & Dohme.
Conflict of interest statement
Barthell, Woelber, Hellner, Camerer, Gieseking, Hauschild, and Friese report having received funding from Merck through their respective institutions to conduct clinical trials of this vaccine. Drs Sings and Barr are employees of Merck and Co., Inc. and hold stock and/or stock options. Dr. Barthell has received lecture fees from speaking at the invitation of Sanofi-Pasteur Merck Sharp & Dohme. Merck Research Laboratories funded this study in its entirety.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barthell, E., Woelber, L., Hellner, K. et al. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Arch Gynecol Obstet 279, 803–807 (2009). https://doi.org/10.1007/s00404-008-0806-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0806-1